With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.
Novo’s High Dose Wegovy Scores FDA Priority Voucher Program’s 4th Nod Read More »
The assets will add AI-backed care navigation capabilities to MedArrive’s home care logistics platform, so health systems can determine which patients are ready to transfer from acute care.
MedArrive acquires tech assets from shuttered Inbound Health Read More »
The head of the American Hospital Association attempted to defend consolidation. Members of a House Energy and Commerce subcommittee were unmoved.
Provider consolidation slammed in latest House affordability hearing Read More »
Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether the agency will agree to approve them is still unknown.
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure Read More »
The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.
AstraZeneca Building Shanghai Production Plant to Support Cell Therapy Strategy Read More »
Eli Lilly’s retatrutide could present a “differentiated option” for patients with type 2 diabetes who want to control their blood sugar and achieve maximal weight loss, according to analysts at BMO Capital Markets.
Lilly Builds Differentiated Profile for Triple-G Agonist With Late-Stage Diabetes Data Read More »
Prime biotech buyout targets such as Revolution Medicines and BioCryst Pharmaceuticals have recently found themselves in the middle of acquisition rumors—though no deals have panned out so far.
Gossamer Bio reported last month that its only late-stage candidate failed a Phase 3 study in pulmonary arterial hypertension, casting doubt on the asset’s future prospects.
Gossamer Nearly Halves Workforce in Savings Push After Late-Stage Hypertension Fail Read More »
Hay enfermedades que guardan sus secretos con una obstinación inesperadamente férrea. La epilepsia es una de ellas. Una minirrevisión de resultados de estudios, publicada recientemente en la revista académica Genomic Psychiatry, sintetiza el panorama en rápida expa …
Miles de variantes genéticas, muchas ocultas, intervienen en la epilepsia Read More »
In this episode of Denatured, you’ll listen to Viswa Colluru, CEO and founder of Enveda and Akshay Rai, principal, Healthcare & Biotech Investments at Premji Invest. We speak about how AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases to garner investor interest.
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms Read More »
